Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-11-2021 | Molecular Imaging | Review Article

The increasing potential of nuclear medicine imaging for the evaluation and reduction of normal tissue toxicity from radiation treatments

Authors: V. Mohan, N. M. Bruin, J. B. van de Kamer, J.-J. Sonke, Wouter V. Vogel

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2021

Abstract

Radiation therapy is an effective treatment modality for a variety of cancers. Despite several advances in delivery techniques, its main drawback remains the deposition of dose in normal tissues which can result in toxicity. Common practices of evaluating toxicity, using questionnaires and grading systems, provide little underlying information beyond subjective scores, and this can limit further optimization of treatment strategies. Nuclear medicine imaging techniques can be utilised to directly measure regional baseline function and function loss from internal/external radiation therapy within normal tissues in an in vivo setting with high spatial resolution. This can be correlated with dose delivered by radiotherapy techniques to establish objective dose-effect relationships, and can also be used in the treatment planning step to spare normal tissues more efficiently. Toxicity in radionuclide therapy typically occurs due to undesired off-target uptake in normal tissues. Molecular imaging using diagnostic analogues of therapeutic radionuclides can be used to test various interventional protective strategies that can potentially reduce this normal tissue uptake without compromising tumour uptake. We provide an overview of the existing literature on these applications of nuclear medicine imaging in diverse normal tissue types utilising various tracers, and discuss its future potential.

Gianfaldoni S, Gianfaldoni R, Wollina U, Lotti J, Tchernev G, Lotti T. An overview on radiotherapy: from its history to its current applications in dermatology. Open Access Maced J Med Sci. 2017;5:521–5.PubMedPubMedCentralCrossRef

Symonds P, Deehan C, Meredeith C, Mills J. Walter & Miller’s textbook of radiotherapy: radiation physics, therapy and oncology. 7th ed: Elsevier Health Sciences; 2012.

Barnett GC, West CML, Dunning AM, Elliott RM, Coles CE, Pharoah PDP, et al. Normal tissue reactions to radiotherapy. Nat Rev Cancer. 2009;9:134–42.PubMedPubMedCentralCrossRef

Zhen Y, Jiang Y, Yuan L, Kirkpartrick J, Wu J, Ge Y. Analyzing the usage of standards in radiation therapy clinical studies. 2017 IEEE EMBS Int Conf Biomed Heal Informatics [Internet]. IEEE; 2017. p. 349–52. Available from: http://ieeexplore.ieee.org/document/7897277/.

Jiang Y, Yuan L, Wu Q, Yin F, Ge Y. Normal tissue toxicity criteria in radiation therapy. Int J Radiat Oncol Biol Phys [Internet]. Elsevier; 2013;87:S621–2. Available from: https://doi.org/10.1016/j.ijrobp.2013.06.1643.

Flores LT, Bennett AV, Law EB, Hajj C, Griffith MP, Goodman KA. Patient-reported outcomes vs. clinician symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res. 2012;5:119–24.PubMedPubMedCentral

Wilkie JR, Mierzwa ML, Yao J, Eisbruch A, Feng M, Weyburne G, et al. Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy. Radiother Oncol [Internet]. Elsevier B.V.; 2019;137:167–74. Available from: https://doi.org/10.1016/j.radonc.2019.04.030.

Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66:445–53.PubMedCrossRef

Beetz I, Burlage FR, Bijl HP, Hoegen-Chouvalova O, Christianen MEMC, Vissink A, et al. The groningen radiotherapy-induced xerostomia questionnaire: Development and validation of a new questionnaire. Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2010;97:127–31. Available from: https://doi.org/10.1016/j.radonc.2010.05.004.

10.

Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol [Internet]. 2011;186:865–72. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf.

11.

Rosen BS, Hawkins PG, Polan DF, Balter JM, Brock KK, Kamp JD, et al. Early changes in serial CBCT-measured parotid gland biomarkers predict chronic xerostomia after head and neck radiation therapy. Int J Radiat Oncol Biol Phys [Internet]. Elsevier Inc.; 2018;102:1319–29. Available from: https://doi.org/10.1016/j.ijrobp.2018.06.048.

12.

Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol. 2007;85:435–42.PubMedCrossRef

13.

Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14:721–40.PubMedCrossRef

14.

Fiorino C, Rizzo G, Scalco E, Broggi S, Belli ML, Dell’Oca I, et al. Density variation of parotid glands during IMRT for head-neck cancer: correlation with treatment and anatomical parameters. Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2012;104:224–9. Available from: https://doi.org/10.1016/j.radonc.2012.06.003.

15.

Cheng SCH, Wu VWC, Kwong DLW, Ying M. Assessment of post-radiotherapy salivary glands. Br J Radiol. 2011;84:393–402.PubMedPubMedCentralCrossRef

16.

Loimu V, Seppälä T, Kapanen M, Tuomikoski L, Nurmi H, Mäkitie A, et al. Diffusion-weighted magnetic resonance imaging for evaluation of salivary gland function in head and neck cancer patients treated with intensity-modulated radiotherapy. Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2017;122:178–84. Available from: https://doi.org/10.1016/j.radonc.2016.07.008.

17.

Vinogradskiy Y, Koo PJ, Castillo R, Castillo E, Guerrero T, Gaspar LE, et al. Comparison of 4-dimensional computed tomography ventilation with nuclear medicine ventilation-perfusion imaging: a clinical validation study. Int J Radiat Oncol Biol Phys [Internet]. Elsevier Inc.; 2014;89:199–205. Available from: https://doi.org/10.1016/j.ijrobp.2014.01.009.

18.

Saif MW, Tzannou I, Makrilia N, Syrigos K. Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med. 2010;83:53–65.PubMedPubMedCentral

19.

Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet [Internet]. 2004;363:1665–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15158627.

20.

Rose BS, Aydogan B, Liang Y, Yeginer M, Hasselle MD, Dandekar V, et al. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:800–7.PubMedCrossRef

21.

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.PubMedCrossRef

22.

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.PubMedCrossRef

23.

Dess RT, Sun Y, Matuszak MM, Sun G, Soni PD, Bazzi L, et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol. 2017;35:1395–402.PubMedPubMedCentralCrossRef

24.

Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631–9.PubMedCrossRef

25.

Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51:1377–85.PubMedCrossRef

26.

Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35:56–62.PubMedCrossRef

27.

Chaudhuri AA, Binkley MS, Rigdon J, Carter JN, Aggarwal S, Dudley SA, et al. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2016;16–21. Available from: https://doi.org/10.1016/j.radonc.2016.05.007.

28.

Marta GN, Silva V, De Andrade Carvalho H, De Arruda FF, Hanna SA, Gadia R, et al. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2014;110:9–15. Available from: https://doi.org/10.1016/j.radonc.2013.11.010.

29.

Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted a-therapy of metastatic castration-resistant prostate cancer with 225 Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802.PubMedCrossRef

30.

Clement SCC, Peeters RPP, Ronckers CMM, Links TPP, van den Heuvel-Eibrink MM, Nieveen van Dijkum EJM, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma – a systematic review. Cancer Treat Rev [Internet]. Elsevier Ltd; 2015;41:925–34. Available from: https://doi.org/10.1016/j.ctrv.2015.09.001.

31.

Yagi M, Froelich J, Arentsen L, Shanley R, Ghebre R, Yee D, et al. Longitudinal FDG-PET revealed regional functional heterogeneity of bone marrow, site-dependent response to treatment and correlation with hematological parameters. J Cancer. 2015;6:531–7.PubMedPubMedCentralCrossRef

32.

McGuire SM, Menda Y, Boles Ponto LL, Gross B, Buatti J, Bayouth JE. 3′-deoxy-3′-[ 18 F]fluorothymidine PET quantification of bone marrow response to radiation dose. Int J Radiat Oncol Biol Phys. 2011;81:888–93.PubMedCrossRefPubMedCentral

33.

Agool A, Slart RHJA, Thorp KK, Glaudemans AWJM, Cobben DCP, Been LB, et al. Effect of radiotherapy and chemotherapy on bone marrow activity: a 18F-FLT-PET study. Nucl Med Commun. 2011;32:17–22.PubMedCrossRef

34.

Robinson M, Muirhead R, Jacobs C, Cooke R, Chu KY, Van den Heuvel F, et al. Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer. Radiother Oncol [Internet]. The Authors; 2020;143:19–23. Available from: https://doi.org/10.1016/j.radonc.2019.08.016.

35.

McGuire SM, Bhatia SK, Sun W, Jacobson GM, Menda Y, Ponto LL, et al. Using [18F]fluorothymidine imaged with positron emission tomography to quantify and reduce hematologic toxicity due to chemoradiation therapy for pelvic cancer patients. Int J Radiat Oncol Biol Phys [Internet]. Elsevier Inc.; 2016;96:228–39. Available from: https://doi.org/10.1016/j.ijrobp.2016.04.009.

36.

Santoro L, Mora-Ramirez E, Trauchessec D, Chouaf S, Eustache P, Pouget JP, et al. Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using 177Lu-[DOTA0, Tyr3]-octreotate. EJNMMI Res. 2018;8.

37.

Hagmarker L, Svensson J, Rydén T, Van Essen M, Sundlöv A, Gleisner KS, et al. Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases. J Nucl Med. 2019;60:1406–13.PubMedCrossRefPubMedCentral

38.

Ahlstedt J, Johansson E, Sydoff M, Karlsson H, Thordarson E, Gram M, et al. Non-invasive imaging methodologies for assessment of radiation damage to bone marrow and kidneys from peptide receptor radionuclide therapy. Neuroendocrinology. 2020;110:130–8.PubMedCrossRef

39.

Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, et al. Radioligand therapy of metastatic prostate cancer using 177Lu- PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget. 2017;8:55567–74.PubMedCrossRefPubMedCentral

40.

Sartor AO, la Fougère C, Essler M, Ezziddin S, Kramer G, Ellinger J, et al. Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223). J Clin Oncol [Internet]. American Society of Clinical Oncology; 2020;38:e17592–e17592. Available from: https://doi.org/10.1200/JCO.2020.38.15_suppl.e17592.

41.

Jacene H, Gomella L, Yu EY, Rohren EM. Hematologic toxicity from radium-223 therapy for bone metastases in castration-resistant prostate cancer: risk factors and practical considerations. Clin Genitourin Cancer [Internet]. Elsevier Inc.; 2018;16:e919–26. Available from: https://doi.org/10.1016/j.clgc.2018.03.007.

42.

Racaru LV, Sinigaglia M, Kanoun S, Ben Bouallègue F, Tal I, Brillouet S, et al. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study. Nucl Med Commun. 2018;39:672–9.CrossRef

43.

Hahn CA, Zhou SM, Raynor R, Tisch A, Light K, Shafman T, et al. Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. Int J Radiat Oncol Biol Phys. 2009;73:1082–7.PubMedCrossRef

44.

Araki Y, Imao Y, Hirata T, Ando T, Sakai N, Yamada H. Cerebral blood flow of the non-affected brain in patients with malignant brain tumors as studied by SPECT; with special reference to adverse effects of radiochemotherapy. No Shinkei Geka [Internet]. 1990;18:601–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2395518.

45.

Eshghi N, Garland LL, Choudhary G, Hsu CC, Eshghi A, Han J, et al. Regional changes in brain 18F-FDG uptake after prophylactic cranial irradiation and chemotherapy in small cell lung cancer may reflect functional changes. J Nucl Med Technol. 2018;46:355–8.PubMedCrossRef

46.

Krull KR, Minoshima S, Edelmann M, Morris B, Sabin ND, Brinkman TM, et al. Regional brain glucose metabolism and neurocognitive function in adult survivors of childhood cancer treated with cranial radiation. J Nucl Med. 2014;55:1805–10.PubMedCrossRef

47.

Ceccon G, Lohmann P, Stoffels G, Judov N, Filss CP, Rapp M, et al. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro-Oncology. 2017;19:281–8.PubMed

48.

Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, et al. Cardiac 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2013;109:82–8. Available from: https://doi.org/10.1016/j.radonc.2013.07.021

49.

Unal K, Mustafa U, Akdemir O, Akmansu M. 18F-FDG PET/CT findings of radiotherapy-related myocardial changes in patients with thoracic malignancies. Nucl Med Commun. 2013;34:855–9.PubMedCrossRef

50.

Gyenes G, Fornander T, Carlens P, Glas U, Rutqvist LE. Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy. Eur J Nucl Med. 1997;24:286–92.PubMed

51.

Seddon B, Cook A, Gothard L, Salmon E, Latus K, Underwood SR, et al. Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol. 2002;64:53–63.PubMedCrossRef

52.

Zyromska A, Małkowski B, Wiśniewski T, Majewska K, Reszke J, Makarewicz R. 15O-H2O PET/CT as a tool for the quantitative assessment of early post-radiotherapy changes of heart perfusion in breast carcinoma patients. Br J Radiol. 2018;91:13–9.

53.

Rasmussen T, Kjær A, Lassen ML, Pedersen AN, Specht L, Aznar MC, et al. No changes in myocardial perfusion following radiation therapy of left-sided breast cancer: a positron emission tomography study. J Nucl Cardiol [Internet]. Springer International Publishing; 2019; Available from: https://doi.org/10.1007/s12350-019-01949-9

54.

Nehmeh SA, Fox JJ, Schwartz J, Ballangrud ÅM, Schöder H, Zhao Y, et al. A pilot study of ¹³N-ammonia cardiac PET imaging to assess subacute cardiotoxicity following adjuvant intensity-modulated radiotherapy for locally advanced breast cancer. Clin Imaging [Internet]. Elsevier; 2020;68:283–90. Available from: https://doi.org/10.1016/j.clinimag.2020.07.026.

55.

Siva S, Jackson P, Kron T, Bressel M, Lau E, Hofman M, et al. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship. Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2016;118:540–6. Available from: https://doi.org/10.1016/j.radonc.2016.01.027.

56.

Ibrahimov R, Atasoy BM, Dede F, Arikan H, Ozen Z, Ozgen Z, et al. Functional and clinical evaluation of renal injury in patients treated with adjuvant chemoradiotherapy for gastric cancer: low dose and comorbidity considerations. J Radiat Res Appl Sci [Internet]. Elsevier Ltd; 2016;9:63–7. Available from: https://doi.org/10.1016/j.jrras.2015.09.004.

57.

Trip AK, Nijkamp J, Van Tinteren H, Cats A, Boot H, Jansen EPM, et al. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer. Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2015;114:421–6. Available from: https://doi.org/10.1016/j.radonc.2015.03.009.

58.

Nishii R, Yamazaki K, Kasuya G, Makishima H, Chang T, Tamura K, et al. Usefulness of 99mTc MAG3 renogram for monitoring before and after carbon ion radiotherapy in patients with renal cell carcinoma. J Nucl Med [Internet]. Society of Nuclear Medicine; 2020 [cited 2020 Oct 17];61:1161–1161. Available from: http://jnm.snmjournals.org/cgi/content/short/61/supplement_1/1161.

59.

Kashyap R, Jackson P, Hofman MS, Eu P, Beauregard JM, Zannino D, et al. Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. Eur J Nucl Med Mol Imaging. 2013;40:1853–60.PubMedCrossRef

60.

Sundlöv A, Sjögreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44:1480–9.PubMedPubMedCentralCrossRef

61.

Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, et al. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1473–9.PubMedCrossRef

62.

Werner RA, Beykan S, Higuchi T, Lückerath K, Weich A, Scheurlen M, et al. The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy. Oncotarget. 2016;7:41233–41.PubMedPubMedCentralCrossRef

63.

Werner RA, Chen X, Lapa C, Koshino K, Rowe SP, Pomper MG, et al. The next era of renal radionuclide imaging: novel PET radiotracers. Eur J Nucl Med Mol Imaging; 2019;46:1773–1786.

64.

Matteucci F, Mezzenga E, Caroli P, Di Iorio V, Sarnelli A, Celli M, et al. Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results. Eur J Nucl Med Mol Imaging. 2017;44:2189–94.PubMedCrossRef

65.

Sarnelli A, Belli ML, Di Iorio V, Mezzenga E, Celli M, Severi S, et al. Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol. Molecules. 2019;24.

66.

Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, et al. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015;56:293–8.PubMedCrossRef

67.

Chatalic KLS, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JDM, Franssen GM, Clahsen-van Groningen MC, et al. Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent. Theranostics. 2016;6:849–61.PubMedPubMedCentralCrossRef

68.

Harsini S, Saprunoff H, Alden TM, Mohammadi B, Wilson D, Benard F. The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study. J Nucl Med. 2020:jnumed.120.246983.

69.

Grant MJ, Didier RA, Stevens JS, Beyder DD, Hunter JG, Thomas CR, et al. Radiation-induced liver disease as a mimic of liver metastases at serial PET/CT during neoadjuvant chemoradiation of distal esophageal cancer. Abdom Imaging. 2014;39:963–8.PubMedPubMedCentralCrossRef

70.

Price RG, Apisarnthanarax S, Schaub SK, Nyflot MJ, Chapman TR, Matesan M, et al. Regional radiation dose-response modeling of functional liver in hepatocellular carcinoma patients with longitudinal sulfur colloid SPECT/CT: a proof of concept. Int J Radiat Oncol Biol Phys [Internet]. Elsevier Inc.; 2018;102:1349–56. Available from: https://doi.org/10.1016/j.ijrobp.2018.06.017.

71.

Wang H, Feng M, Frey KA, Ten Haken RK, Lawrence TS, Cao Y. Predictive models for regional hepatic function based on 99mTc-IDA SPECT and local radiation dose for physiologic adaptive radiation therapy. Int J Radiat Oncol [Internet]. 2013;86:1000–6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301613003970.

72.

Shen S, Jacob R, Bender LW, Duan J, Spencer SA. A technique using 99mTc-mebrofenin SPECT for radiotherapy treatment planning for liver cancers or metastases. Med Dosim [Internet]. Elsevier; 2014;39:7–11. Available from: https://doi.org/10.1016/j.meddos.2013.08.006.

73.

Toya R, Saito T, Kai Y, Shiraishi S, Matsuyama T, Watakabe T, et al. Impact of 99mTc-GSA SPECT image-guided inverse planning on dose–function histogram parameters for stereotactic body radiation therapy planning for patients with hepatocellular carcinoma: a dosimetric comparison study. Dose-Response. 2019;17:1–6.CrossRef

74.

Gates VL, Singh N, Lewandowski RJ, Spies S, Salem R. Intraarterial hepatic SPECT/CT imaging using 99mTc-macroaggregated albumin in preparation for radioembolization. J Nucl Med. 2015;56:1157–62.PubMedCrossRef

75.

Song YS, Paeng JC, Kim H, Chung JW, Cheon GJ, Chung J-K, et al. PET/CT-based dosimetry in 90Y-microsphere selective internal radiation therapy. Medicine (Baltimore) [Internet]. 2015;94:e945. Available from: http://journals.lww.com/00005792-201506020-00024.

76.

Alsultan AA, Smits MLJ, Barentsz MW, Braat AJAT, Lam MGEH. The value of yttrium - 90 PET / CT after hepatic radioembolization : a pictorial essay. Clin Transl Imaging [Internet]. Springer International Publishing; 2019;7:303–12. Available from: https://doi.org/10.1007/s40336-019-00335-2.

77.

Roach PJ, Schembri GP, Bailey DL. V/Q scanning using SPECT and SPECT/CT. J Nucl Med. 2013;54:1588–96.PubMedCrossRef

78.

Bajc M, Schümichen C, Grüning T, Lindqvist A, Le Roux PY, Alatri A, et al. EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. Eur J Nucl Med Mol Imaging. 2019;46:2429–51.PubMedCrossRefPubMedCentral

79.

Jögi J, Jonson B, Ekberg M, Bajc M. Ventilation-perfusion SPECT with 99mTc-DTPA versus Technegas: a head-to-head study in obstructive and nonobstructive disease. J Nucl Med. 2010;51:735–41.PubMedCrossRef

80.

Marks LB, Munley MT, Spencer DP, Sherouse GW, Bentel GC, Hoppenworth J, et al. Quantification of radiation-induced regional lung injury with perfusion imaging. Int J Radiat Oncol Biol Phys. 1997;38:399–409.PubMedCrossRef

81.

Seppenwoolde Y, Muller SH, Theuws JCM, Baas P, Belderbos JSA, Boersma LJ, et al. Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;47:681–90.PubMedCrossRef

82.

Zhang J, Ma J, Zhou S, Hubbs JL, Wong TZ, Folz RJ, et al. Radiation-induced reductions in regional lung perfusion: 0.1-12 year data from a prospective clinical study. Int J Radiat Oncol Biol Phys. 2010;76:425–32.PubMedCrossRef

83.

Thomas HMT, Zeng J, Lee HJ, Sasidharan BK, Kinahan PE, Miyaoka RS, et al. Comparison of regional lung perfusion response on longitudinal MAA SPECT/CT in lung cancer patients treated with and without functional tissue-avoidance radiation therapy. Br J Radiol. 2019;92.

84.

Scheenstra AEH, Rossi MMG, Belderbos JSA, Damen EMF, Lebesque J V., Sonke JJ. Local dose-effect relations for lung perfusion post stereotactic body radiotherapy. Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2013;107:398–402. Available from: https://doi.org/10.1016/j.radonc.2013.04.003.

85.

Gayed IW, Chang J, Kim EE, Nuñez R, Chasen B, Liu HH, et al. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol [Internet]. 2008;3:858–64. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1556086415304494.

86.

Weller A, Dunlop A, Oxer A, Gunapala R, Murray I, Gray MJ, et al. Spect perfusion imaging versus CT for predicting radiation injury to normal lung in lung cancer patients. Br J Radiol. 2019;92:1–9.CrossRef

87.

Christian JA, Partridge M, Nioutsikou E, Cook G, Mcnair HA, Cronin B, et al. The incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancer. Radiother Oncol. 2005;77:271–7.PubMedCrossRef

88.

Selvaray J, Lebesque J, Hope A, Guckenberger M, Werner-Wasik M, Peulen H, et al. Modeling radiation pneumonitis of pulmonary stereotactic body radiotherapy: the impact of a local dose–effect relationship for lung perfusion loss. Radiother Oncol [Internet]. Elsevier B.V.; 2019;132:142–7. Available from: https://doi.org/10.1016/j.radonc.2018.12.015.

89.

Yuan S, Frey KA, Gross MD, Hayman JA, Arenberg D, Curtis JL, et al. Semiquantification and classification of local pulmonary function by V/Q single photon emission computed tomography in patients with non-small cell lung cancer: potential indication for radiotherapy planning. J Thorac Oncol [Internet]. Elsevier; 2011;6:71–8. Available from: https://doi.org/10.1097/JTO.0b013e3181f77b40.

90.

Le Roux PY, Hicks RJ, Siva S, Hofman MS. PET/CT lung ventilation and perfusion scanning using galligas and gallium-68-MAA. Semin Nucl Med [Internet]. Elsevier Inc.; 2019;49:71–81. Available from: https://doi.org/10.1053/j.semnuclmed.2018.10.013.

91.

Siva S, Thomas R, Callahan J, Hardcastle N, Pham D, Kron T, et al. High-resolution pulmonary ventilation and perfusion PET/CT allows for functionally adapted intensity modulated radiotherapy in lung cancer. Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2015;115:157–62. Available from: https://doi.org/10.1016/j.radonc.2015.04.013.

92.

Siva S, Hardcastle N, Kron T, Bressel M, Callahan J, MacManus MP, et al. Ventilation/perfusion positron emission tomography - based assessment of radiation injury to lung. Int J Radiat Oncol Biol Phys [Internet]. Elsevier Inc; 2015;93:408–17. Available from: https://doi.org/10.1016/j.ijrobp.2015.06.005.

93.

Iravani A, Turgeon GA, Akhurst T, Callahan JW, Bressel M, Everitt SJ, et al. PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. Eur J Nucl Med Mol Imaging. 2019;46:1869–77.PubMedCrossRef

94.

Hart JP, McCurdy MR, Ezhil M, Wei W, Khan M, Luo D, et al. Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response. Int J Radiat Oncol [Internet]. 2008;71:967–71. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301608005828.

95.

Mccurdy MR, Castillo R, Martinez J, Najeeb M, Hallack A, Lichter J, et al. [ 18 F ] -FDG uptake dose response correlates with radiation pneumonitis in lung cancer patients. Radiother Oncol [Internet]. Elsevier Ireland Ltd; 2012;104:52–7. Available from: https://doi.org/10.1016/j.radonc.2012.04.003.

96.

Guerrero T, Johnson V, Hart J, Pan T, Khan M, Luo D, et al. Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol [Internet]. 2007;68:1030–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20884128

97.

Siva S, Callahan JW, Kron T, Chesson B, Barnett SA, MacManus MP, et al. Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases. Acta Oncol (Madr). 2015;54:1105–12.CrossRef

98.

Petit SF, van Elmpt WJC, Oberije CJG, Vegt E, Dingemans A-MC, Lambin P, et al. [¹⁸F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients. Int J Radiat Oncol Biol Phys [Internet]. 2011;81:698–705. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20884128.

99.

Castillo R, Pham N, Ansari S, Meshkov D, Castillo S, Li M, et al. Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer. Radiat Oncol [Internet]. Radiation Oncology; 2014;9:1–10. Available from: Radiation Oncology.

100.

Tenhunen M, Collan J, Kouri M, Kangasmäki A, Heikkonen J, Kairemo K, et al. Scintigraphy in prediction of the salivary gland function after gland-sparing intensity modulated radiation therapy for head and neck cancer. Radiother Oncol. 2008;87:260–7.PubMedCrossRef

101.

Van Acker F, Flamen P, Lambin P, Maes A, Kutcher GJ, Weltens C, et al. The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy. Nucl Med Commun. 2001;22:225–31.PubMedCrossRef

102.

Bussels B, Maes A, Flamen P, Lambin P, Erven K, Hermans R, et al. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol. 2004;73:297–306.PubMedCrossRef

103.

Buus S, Grau C, Munk OL, Rodell A, Jensen K, Mouridsen K, et al. Individual radiation response of parotid glands investigated by dynamic 11C-methionine PET. Radiother Oncol. 2006;78:262–9.PubMedCrossRef

104.

Roach MC, Turkington TG, Higgins KA, Hawk TC, Hoang JK, Brizel DM. FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism. Int J Radiat Oncol Biol Phys. 2012;82:321–6.PubMedCrossRef

105.

Cannon B, Schwartz DL, Dong L. Metabolic imaging biomarkers of postradiotherapy xerostomia. Int J Radiat Oncol Biol Phys. 2012;83:1609–16.PubMedPubMedCentralCrossRef

106.

Valstar MH, Owers EC, Al-Mamgani A, Smeele LE, van de Kamer JB, Sonke JJ, et al. Prostate-specific membrane antigen positron emission tomography/computed tomography as a potential tool to assess and guide salivary gland irradiation. Phys Imaging Radiat Oncol [Internet]. Elsevier; 2019;9:65–8. Available from: https://doi.org/10.1016/j.phro.2019.02.004.

107.

Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med. 2002;27:767–71.PubMedCrossRef

108.

Mandel L, Liu F. Salivary gland injury resulting from exposure to radioactive iodine. J Am Dent Assoc [Internet]. American Dental Association; 2007;138:1582–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002817714638046.

109.

Mohan V, Vogel WV, Valk GD, de Boer JP, Lam MGEH, de Keizer B. PSMA PET/CT identifies intrapatient variation in salivary gland toxicity from iodine-131 therapy. Mol Imaging. 2020;19:1–7.CrossRef

110.

Haghighatafshar M, Ghaedian M, Etemadi Z, Entezarmahdi SM, Ghaedian T. Pilocarpine effect on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine. Nucl Med Commun. 2018;39:430–4.PubMedCrossRef

111.

Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med [Internet]. 2005;46:261–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16330579.

112.

Ma C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:1778–85.PubMedCrossRef

113.

Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging. 2010;37:2298–306.PubMedCrossRef

114.

Kulkarni K, Van Nostrand D, Atkins F, Mete M, Wexler J, Wartofsky L. Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered? Nucl Med Commun 2014;35:210–216.

115.

van Kalmthout LWM, Lam MGEH, de Keizer B, Krijger GC, Ververs TFT, de Roos R, et al. Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands. EJNMMI Res. 2018;8.

116.

Rousseau E, Lau J, Kuo HT, Zhang Z, Merkens H, Hundal-Jabal N, et al. Monosodium glutamate reduces68Ga-PSMA-11 uptake in salivary glands and kidneys in a preclinical prostate cancer model. J Nucl Med. 2018;59:1865–8.PubMedPubMedCentralCrossRef

117.

Baum RP, Langbein T, Singh A, Shahinfar M, Schuchardt C, Volk GF, et al. Injection of botulinum toxin for preventing salivary gland toxicity after PSMA Radioligand therapy: an empirical proof of a promising concept. Nucl Med Mol Imaging (2010). Nucl Med Mol Imaging; 2018;52:80–81.

118.

Nijkamp J, Rossi M, Lebesque J, Belderbos J, Van Den Heuvel M, Kwint M, et al. Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol [Internet]. 2013;106:118–23. Available from: https://doi.org/10.1016/j.radonc.2012.09.024.

119.

Yuan ST, Brown RKJ, Zhao L, Ten Haken RK, Gross M, Cease KB, et al. Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy. Radiat Oncol [Internet]. Radiation Oncology; 2014;9:1–6. Available from: Radiation Oncology.

120.

Mehmood Q, Sun A, Becker N, Higgins J, Marshall A, Le LW, et al. Predicting radiation esophagitis using 18F-FDG PET during chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol [Internet]. Elsevier Inc; 2016;11:213–21. Available from: https://doi.org/10.1016/j.jtho.2015.10.006.

121.

Dornfeld K, Hopkins S, Simmons J, Spitz DR, Menda Y, Graham M, et al. Posttreatment FDG-PET uptake in the supraglottic and glottic larynx correlates with decreased quality of life after chemoradiotherapy. Int J Radiat Oncol [Internet]. 2008;71:386–92. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301607043714.

122.

Singh U, Walls GM, Hanna GG, Lynch TB, McAleese J. PET/CT features of lung SABR chest wall toxicity. J Med Imaging Radiat Oncol. 2020:2–4.

123.

Kesch C, Kratochwil C, Mier W, Kopka K, Giesel FL. 68Ga or 18F for prostate cancer imaging? J Nucl Med. 2017;58:687–8.PubMedCrossRef

Title: The increasing potential of nuclear medicine imaging for the evaluation and reduction of normal tissue toxicity from radiation treatments
Authors: V. Mohan
N. M. Bruin
J. B. van de Kamer
J.-J. Sonke
Wouter V. Vogel
Publication date: 01-11-2021
Publisher: Springer Berlin Heidelberg
Keywords: Molecular Imaging
Radiotherapy
Positron Emission Tomography
Radionuclide Therapy
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05284-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The increasing potential of nuclear medicine imaging for the evaluation and reduction of normal tissue toxicity from radiation treatments

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2021

International consensus on the use of [18F]-FDG PET/CT in pediatric patients affected by epilepsy

Can someone look after my children while I write this COVID-19 paper?

Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy

Effects of two patient-specific dosing protocols on measurement of myocardial blood flow with 3D 82Rb cardiac PET

Gender balance in the editorial board of nuclear medicine journals

PET imaging of neural activity, β-amyloid, and tau in normal brain aging